In a significant breakthrough for pancreatic cancer treatment, Revolution Medicines announced that its experimental drug, daraxonrasib, has shown remarkable results in a Phase 3 clinical trial. The drug reportedly nearly doubled the average survival time of patients while substantially reducing the risk of death compared to traditional chemotherapy treatments.
According to the company, participants using daraxonrasib had a median survival of 13.2 months, compared to just 6.7 months for those receiving chemotherapy. This translates to an impressive increase of 6.5 months in survival time. Mark Goldsmith, CEO of Revolution Medicines, described the trial outcomes as “dramatic” and “practice-changing,” emphasizing the urgency to make this new treatment available to patients in need. He noted that no other drug has demonstrated a greater overall survival benefit in a Phase 3 trial for pancreatic cancer.
The company is preparing to request approval from the Food and Drug Administration (FDA) leveraging a Commissioner’s National Priority Voucher, a mechanism that allows expedited review of promising new treatments. This approval is particularly critical considering pancreatic cancer’s grim statistics; it carries the lowest five-year survival rate of any major cancer type, with only 13% of patients surviving five years post-diagnosis.
Daraxonrasib targets RAS mutations that are present in about 90% of pancreatic cancer cases and represent a significant driver of tumor growth. Goldsmith highlighted the importance of this new approach, noting that pancreatic cancer treatments have been primarily limited to cytotoxic intravenous chemotherapy until now. The positive safety profile of daraxonrasib was also noted, with no new safety concerns arising during the trial. While the drug is associated with side effects like rash, Goldsmith assured that these are manageable, a sentiment echoed by former Republican Senator Ben Sasse who recently discussed his own experience with the medication.
Currently, the company is not only seeking approval for daraxonrasib as a second-line treatment for patients whose cancer has advanced despite prior therapy but is also conducting a separate Phase 3 trial for newly diagnosed patients. Following the announcement of the positive trial results, Revolution Medicines’ stock surged by more than 30%.
